Terms: = Prostate cancer AND PWWP2A, Q8IYR3_HUMAN, Q96N64, MST101, MGC132770, KIAA1935, ENSG00000170234, 114825
26647 results:
1. Antiproliferative and Apoptotic Effects of Murici (Byrsonima crassifolia (L.) Kunth and verbascifolia (L.) DC) and Taperebá (Spondias mombin L.) Extracts in Human prostate Cell Line (PC-3).
Amaral Muxfeldt Paim TOD; Simas NF; Abreu JP; Rosa L; Passos Barbosa Lima T; Teodoro AJ
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1339-1347. PubMed ID: 38679995
[TBL] [Abstract] [Full Text] [Related]
2. Patient-Derived Xenograft Models for Translational prostate cancer Research and Drug Development.
Philp LK
Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
[TBL] [Abstract] [Full Text] [Related]
3. Genomic Frequencies of Dynamic DNA Sequences and Mammalian Lifespan.
Martella M; Carlesso N; Waller ZAE; Marcucci G; Pichiorri F; Smith SS
Cancer Genomics Proteomics; 2024; 21(3):238-251. PubMed ID: 38670588
[TBL] [Abstract] [Full Text] [Related]
4. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract] [Full Text] [Related]
5. AZGP1 deficiency promotes angiogenesis in prostate cancer.
Wen RM; Qiu Z; Marti GEW; Peterson EE; Marques FJG; Bermudez A; Wei Y; Nolley R; Lam N; Polasko AL; Chiu CL; Zhang D; Cho S; Karageorgos GM; McDonough E; Chadwick C; Ginty F; Jung KJ; Machiraju R; Mallick P; Crowley L; Pollack JR; Zhao H; Pitteri SJ; Brooks JD
J Transl Med; 2024 Apr; 22(1):383. PubMed ID: 38659028
[TBL] [Abstract] [Full Text] [Related]
6. High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue.
Zhang N; Harbers L; Simonetti M; Diekmann C; Verron Q; Berrino E; Bellomo SE; Longo GMC; Ratz M; Schultz N; Tarish F; Su P; Han B; Wang W; Onorato S; Grassini D; Ballarino R; Giordano S; Yang Q; Sapino A; Frisén J; Alkass K; Druid H; Roukos V; Helleday T; Marchiò C; Bienko M; Crosetto N
Nat Commun; 2024 Apr; 15(1):3475. PubMed ID: 38658552
[TBL] [Abstract] [Full Text] [Related]
7. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract] [Full Text] [Related]
8. Developing a Novel Enzalutamide-Resistant prostate cancer Model via AR F877L Mutation in LNCaP Cells.
Wang R; Ma S; Xu N; Gan Y; Li P; Zhang J; Zhang Z; Gu Q; Xiang J
Curr Protoc; 2024 Apr; 4(4):e1033. PubMed ID: 38652202
[TBL] [Abstract] [Full Text] [Related]
9. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
[TBL] [Abstract] [Full Text] [Related]
10. [Explore the mechanism of astragaloside IV-PESV on proliferation, migration, and autophagy of prostate cancer cells based on the PI3K/AKT signaling pathway].
You XJ; Wen Z; Zheng QX; Li QX; Fu W; Li HS; Wang B
Zhonghua Nan Ke Xue; 2023 Dec; 29(12):963-972. PubMed ID: 38639947
[TBL] [Abstract] [Full Text] [Related]
11. DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.
Li X; Yao J; Qu C; Luo L; Li B; Zhang Y; Zhu Z; Qiu Y; Hua H
J Transl Med; 2024 Apr; 22(1):362. PubMed ID: 38632563
[TBL] [Abstract] [Full Text] [Related]
12. ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance.
Lee CJ; Lee H; Kim SR; Nam SB; Lee GE; Yang KE; Lee GJ; Chun SH; Kang HC; Lee JY; Lee HS; Cho SJ; Cho YY
Cell Death Dis; 2024 Apr; 15(4):274. PubMed ID: 38632244
[TBL] [Abstract] [Full Text] [Related]
13. Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer: a structure-based in-silico approach.
Alsaiari AA; Gharib AF; Bakhuraysah MM; Alrehaili AA; Algethami SM; Alsaif HA; Al Harthi N; Hakami MA
Med Oncol; 2024 Apr; 41(5):117. PubMed ID: 38630325
[TBL] [Abstract] [Full Text] [Related]
14. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract] [Full Text] [Related]
15. Abscisic acid signaling through LANCL2 and PPARγ induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells.
Parajuli KR; Jung Y; Taichman RS
Oncol Rep; 2024 Mar; 51(3):. PubMed ID: 38624012
[TBL] [Abstract] [Full Text] [Related]
16. Isolation, Identification and Chemical Modification of Bufadienolides from
Ye Q; Lin R; Chen Z; Li J; Zheng C
Molecules; 2024 Mar; 29(7):. PubMed ID: 38611850
[TBL] [Abstract] [Full Text] [Related]
17. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy.
Feng DC; Zhu WZ; Wang J; Li DX; Shi X; Xiong Q; You J; Han P; Qiu S; Wei Q; Yang L
Mil Med Res; 2024 Apr; 11(1):21. PubMed ID: 38605399
[TBL] [Abstract] [Full Text] [Related]
18. Interference with mitochondrial metabolism could serve as a potential therapeutic strategy for advanced prostate cancer.
Wu C; Zhu H; Zhang Y; Ding L; Wang J
PLoS One; 2024; 19(4):e0290753. PubMed ID: 38598542
[TBL] [Abstract] [Full Text] [Related]
19. A genome-wide association study provides insights into the genetic etiology of 57 essential and non-essential trace elements in humans.
Moksnes MR; Hansen AF; Wolford BN; Thomas LF; Rasheed H; Simić A; Bhatta L; Brantsæter AL; Surakka I; Zhou W; Magnus P; Njølstad PR; Andreassen OA; Syversen T; Zheng J; Fritsche LG; Evans DM; Warrington NM; Nøst TH; Åsvold BO; Flaten TP; Willer CJ; Hveem K; Brumpton BM
Commun Biol; 2024 Apr; 7(1):432. PubMed ID: 38594418
[TBL] [Abstract] [Full Text] [Related]
20. CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors.
Archer S; Brailey PM; Song M; Bartlett PD; Figueiredo I; Gurel B; Guo C; Brucklacher-Waldert V; Thompson HL; Akinwale J; Boyle SE; Rossant C; Birkett NR; Pizzey J; Maginn M; Legg J; Williams R; Johnston CM; Bland-Ward P; de Bono JS; Pierce AJ
Clin Cancer Res; 2024 Apr; 30(8):1595-1606. PubMed ID: 38593226
[TBL] [Abstract] [Full Text] [Related]
[Next]
